affron (R) a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo controlled clinical trial
Contribution to Journal
|ERA Journal ID||34134|
|Authors||Kell, Graham (Author), Rao, Amanda (Author), Beccaria, Gavin (Author), Clayton, Paul (Author), Inarejos-Garcia, Antonio Manuel (Author), Prodanov, Marin (Author), Kell, Graham, Rao, Amanda, Beccaria, Gavin, Clayton, Paul, Manuel Inarejos-Garcia, Antonio and Prodanov, Marin|
|Journal Title||Complementary Therapies in Medicine|
|Journal Citation||33, pp. 58-64|
|Number of Pages||7|
|Place of Publication||United Kingdom|
|Digital Object Identifier (DOI)||https://doi.org/10.1016/j.ctim.2017.06.001|
|Web Address (URL)||http://www.sciencedirect.com/science/article/pii/S0965229917300821|
Background: In recent years phytotherapy has been explored as a source for alternative treatments for mood disorders. One potential candidate is saffron (Crocus sativus L.), whose main bioactive components are crocins and safranal.
Objectives: The aim of this study was to investigate the efficacy of affron®, a standardised stigmas extract from Crocus sativus L. for improving mood, stress, anxiety and sleep quality in healthy adults.
Methods: In this 3 arm study, 128 participants self-reporting low mood but not diagnosed with depression, were given affron® at 28 mg/day, 22 mg/day, or a placebo treatment in a randomized, double-blind, placebo-controlled trial for 4 weeks. Mood was measured at baseline and at the end of the study, using the POMS (primary outcome measure) and PANAS questionnaires, and the DASS-21 scale. Sleep was monitored using Sleep Quality Index (PSQI).
Results: Analysis indicated a significant decrease in negative mood and symptoms related to stress and anxiety at a 28 mg/day dose (with a significant difference between 28 mg/day and placebo on the POMS Total Mood Disturbance scale, p < 0.001, d = −1.10), but no treatment effect at the 22 mg/day dose.
Limitations: The main weaknesses of this investigation were found in the self-reporting nature of both the screening and the testing.
Conclusions: affron® increased mood, reduced anxiety and managed stress without side effects, offering a natural alternative to standard treatments.
|Keywords||Clinical trial; Mood disorders; Saffron extract; Phytonutrient; Depression|
|Contains Sensitive Content||Does not contain sensitive content|
|ANZSRC Field of Research 2020||321499. Pharmacology and pharmaceutical sciences not elsewhere classified|
Files associated with this item cannot be displayed due to copyright restrictions.
|Byline Affiliations||School of Psychology and Counselling|
|RDC Clinical, Australia|
|Institute for Food Brain and Behaviour, United Kingdom|
|Pharmactive Biotech Products, Spain|
|Food Science Research Institute, Spain|
|Institution of Origin||University of Southern Queensland|
|Title||affron (R) a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo controlled clinical trial|
1views this month
0downloads this month